PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?

被引：13
作者：
Cainzos-Achirica, Miguel [1 ]
Martin, Seth S. [1 ]
Cornell, John E.
Murow, Cynthia D.
Guallar, Eliseo
机构：
[1] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2015年 / 163卷 / 01期
关键词：
HYPERCHOLESTEROLEMIA; LDL;
D O I：
10.7326/M15-0920
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：64 / 65
页数：2
相关论文
共 50 条
  • [41] Safety and Tolerability of PCSK9 Inhibitors: Current Insights
    Kosmas, Constantine E.
    Skavdis, Andreas
    Sourlas, Andreas
    Papakonstantinou, Evangelia J.
    Genao, Edilberto Pena
    Uceta, Rogers Echavarria
    Guzman, Eliscer
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2020, 12 : 191 - 202
  • [42] Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
    Seidah, Nabil G.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (17) : 3161 - 3172
  • [43] PCSK9 inhibitors in clinical practice: Delivering on the promise?
    Stoekenbroek, Robert M.
    Hartgers, Merel L.
    Rutte, Roger
    de Wijer, Douwe D.
    Stroes, Erik S. G.
    Hovingh, G. Kees
    ATHEROSCLEROSIS, 2018, 270 : 205 - 210
  • [44] JCL roundtable: PCSK9 inhibitors in clinical practice
    Brown, W. Virgil
    Moriarty, Patrick M.
    McKenney, James M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (01) : 5 - 14
  • [45] Application of PCSK9 Inhibitors in Practice Challenges and Opportunities
    Kaufman, Tina M.
    Duell, P. Barton
    Purnell, Jonathan Q.
    Wojcik, Cezary
    Fazio, Sergio
    Shapiro, Michael D.
    CIRCULATION RESEARCH, 2017, 121 (05) : 499 - +
  • [46] PCSK9 inhibitors: What place in the management of dyslipidemia?
    Sabouret, Pierre
    Farnier, Michel
    Puymirat, Etienne
    PRESSE MEDICALE, 2019, 48 (03): : 227 - 237
  • [47] Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
    Volkova, S. Yu.
    Boyarskaya, L. A.
    Toropygin, P. Yu.
    Morozov, I. A.
    Boyarskaya, E. A.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2023, 19 (01) : 43 - 49
  • [48] PCSK9 Inhibitors: Lots of Work Done, Lots More to Do
    Lauer, Michael S.
    ANNALS OF INTERNAL MEDICINE, 2016, 164 (09) : 624 - 625
  • [49] THERAPY PCSK9 inhibitors for treating familial hypercholesterolaemia
    Mabuchi, Hiroshi
    Nohara, Atsushi
    NATURE REVIEWS ENDOCRINOLOGY, 2015, 11 (01) : 8 - 9
  • [50] What is the role of PCSK9 inhibitors in treating hypercholesterolemia?
    Volpe, Mark
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2018, 31 (06): : 14 - 15
12345